Press Release: Novartis: Sandoz and Pear -2-

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As

a division of the Novartis Group, our purpose is to discover new ways to

improve and extend people's lives. We contribute to society's ability to

support growing healthcare needs by pioneering novel approaches to help

people around the world access high-quality medicine. Our portfolio of

approximately 1000 molecules, covering all major therapeutic areas,

accounted for 2017 sales of USD 10.1 billion. In 2017, our products

reached well over 500 million patients. Sandoz is headquartered in

Holzkirchen, in Germany's Greater Munich area. Sandoz is on Twitter.

Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

Follow our blog at www.sandoz.com/makingaccesshappen.

About Pear Therapeutics

Pear Therapeutics is the leader in prescription digital therapeutics. We

aim to redefine medicine by discovering, developing, and delivering

clinically validated software-based therapeutics to provide better

outcomes for patients, smarter engagement and tracking tools for

clinicians, and cost-effective solutions for payers. Pear has a pipeline

of products and product candidates across therapeutic areas, including

severe psychiatric and neurological conditions. Our lead product,

reSET(R), treats Substance Use Disorder and was the first prescription

digital therapeutic to receive marketing authorization from the FDA to

treat disease. Pear's second product, reSET-O(TM), for the treatment of

Opioid Use Disorder, received marketing clearance from the FDA in

December 2018. For more information, visit us at

www.peartherapeutics.com.

* reSET-O(TM) and reSET(R) are registered trademarks of Pear

Therapeutics, Inc.

References:

[i.] Weisner C et al. Short-term alcohol and drug treatment outcomes

predict long-term outcome. Drug and Alcohol Dependence. 2003. 71:

281-294.

[ii.] CDC/NCHS, National Vital Statistics System, Mortality. CDC

Wonder, Atlanta, GA: US Department of Health and Human Services, CDC;

2017. https://wonder.cdc.gov.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff

Novartis Global Media Relations

+41 61 324 7999 (direct)

+41 79 593 4202 (mobile)

eric.althoff@novartis.com

Chris Lewis Leslie Pott

Sandoz Global Communications Sandoz US Communications

+49 174 244 9501 (mobile) +1 609 627 5287

chris.lewis@sandoz.com leslie.pott@sandoz.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2230718/876668.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

January 07, 2019 17:02 ET (22:02 GMT)